Computational molecular docking assessment of hormone receptor adjuvant drugs: Breast cancer as an example

Pathophysiology : the Official Journal of the International Society for Pathophysiology
Sayan Mukherjee, Durjoy Majumder

Abstract

For the maintenance therapy of breast cancer, drugs which act as antagonists/partial agonists of hormone receptors against the breast tissue are used in the conventional clinical practices. However, during the course of treatment the patients may encounter systems related complications. Drugs like tamoxifen, which block the action of estrogens at its receptors in mammary gland; and the recently designed antiestrogens and selective estrogen receptor modulators (SERM) like raloxifene, toremifene and the progesterone antagonist mifepristone (RU-486) are used in the treatment for estrogen and/or progesterone receptor positive breast tumors. These drugs show, however, both acute and long-term toxicity like endometrial hyperplasia and cancer, menopausal symptoms, edema, thromboembolic events like pulmonary embolism and so on. Using molecular docking method, we studied the binding of these drugs at an array of receptors present within the physiological system. In addition, the molecular basis of the antiglucocorticoid and antiandrogenic side effects of mifepristone have also been studied. Our results show weak to moderate binding of these drugs at various receptors of the body. This may explain the toxicity and pathophysiological shif...Continue Reading

References

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·D de VosR J Briggs
Mar 15, 1996·American Journal of Epidemiology·I RomieuR Romero-Jaime
Oct 28, 1998·Journal of the National Cancer Institute·R M O'ReganV C Jordan
Mar 6, 1999·Breast Cancer Research and Treatment·C K Osborne
Dec 11, 1999·Nucleic Acids Research·H M BermanP E Bourne
Feb 23, 2002·European Journal of Obstetrics, Gynecology, and Reproductive Biology·N N Sarkar
Mar 19, 2002·The Journal of Steroid Biochemistry and Molecular Biology·G ShyamalaS Nandi
Nov 3, 2004·Nature Reviews. Drug Discovery·Douglas B KitchenJürgen Bajorath
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leena VehmanenTiina Saarto
May 10, 2006·PLoS Medicine·Andrew C AhnRussell S Phillips
Aug 22, 2007·IET Systems Biology·O Wolkenhauer
Aug 31, 2007·Nature Clinical Practice. Oncology·Susana BanerjeeLesley-Ann Martin
Oct 3, 2007·IET Systems Biology·D Majumder, A Mukherjee

❮ Previous
Next ❯

Citations

Sep 16, 2011·Advances and Applications in Bioinformatics and Chemistry : AABC·Tarique N HasanP Sivashanmugham
Oct 22, 2010·Environmental Toxicology and Chemistry·Malin C CelanderJames R Wheeler
Oct 27, 2018·Chemistry Central Journal·Deepika SharmaBalasubramanian Narasimhan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Addison Disease

Addison's disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Discover the latest research on Addison's disease here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.